(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/123410 A1

(51) International Patent Classification:
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2019/065294

(22) International Filing Date:
09 December 2019 (09.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/777,677 10 December 2018 (10.12.2018) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **MURRAY, Justin K.**; One Amgen Center Drive, Law Dept - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **WU, Bin**; One Amgen Center Drive, Law Dept - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **CHENG, Yuan**; One Amgen Center Drive, Law Dept - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **HERBERICH, Bradley J.**; One Amgen Center Drive, Law Dept - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **PURCELL, Angela L.**; One Amgen Center Drive, Law Dept - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

(57) **Abstract:** The present invention relates to chemically-modified RNAi constructs for reducing expression of a target gene. In particular, the invention relates to specific patterns of modified nucleotides to be incorporated into RNAi constructs to improve *in vivo* stability and efficacy. Also described are pharmaceutical compositions comprising the chemically-modified RNAi constructs and methods of inhibiting target gene expression *in vivo* by administering the chemically-modified RNAi constructs, for example, to treat or ameliorate various disease conditions.

WO 2020/123410 A1